SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge following an earnings report that blew past expectations, with the community actively debating whether this signals a genuine turnaround driven by AI and foundry strategy or if the stock is overextended. Traders are reacting to the news with intense bullish sentiment, highlighting a structural breakout, while others are cautioning against the valuation as short-squeeze momentum intensifies.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened market activity following news that Uber increased its stake in the company and expanded their robotaxi partnership, fueling active community debates over potential short squeeze scenarios versus ongoing concerns regarding cash burn and dilution. Investors are closely monitoring price action as the stock attempts to find a floor amid heavy short interest and speculative betting on a broader recovery.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing extreme volatility and heavy community engagement following a court verdict where a jury awarded significant damages against a competitor for deceptive practices. Traders are actively debating the stock's potential for a massive short squeeze due to the company's tight float and the scale of the potential legal windfall, while others express caution regarding the long-term collectability of the settlement and the risk of price manipulation.

ASGN Incorporated engages in the provision of information technology services and solutions. It operates through the Commercial and Federal Government segments. The Commercial segment involves the provision of consulting, creative digital marketing, and permanent placement services. The Federal Government segment provides mission-critical solutions. The company was founded on December 30, 1985 and is headquartered in Glen Allen, VA.

ASGN Inc

ASGN Inc. is trending as investors digest the company's rebranding to Everforth (ticker: EFOR) alongside significant stock price volatility. The community remains deeply divided, with some participants viewing the steep sell-off as an attractive buying opportunity based on profitability, while others express strong skepticism, labeling the price action as manipulative and raising concerns over the company's market position.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is gaining momentum as investors focus on its strong developer activity, recent BTCFi integrations, and a roadmap prioritizing privacy and quantum resistance. Community discussions highlight the project's technical moat in ZK-STARK architecture and its growing revenue metrics, which many see as a catalyst for potential long-term growth despite recent supply-related price headwinds.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing significant volatility and high trading volume following earnings, with the community actively debating whether recent progress in solid-state battery manufacturing justifies the momentum or if the price action is driven by a short squeeze. Investors are heavily focused on the company's expansion into non-automotive sectors like AI data centers and defense, while bulls and bears clash over the long-term viability of their production ramp-up versus concerns about historical share dilution.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. is currently the subject of intense M&A speculation, with investors reacting to reports of potential binding acquisition offers from Sun Pharmaceutical and other interested parties. The community is actively debating the credibility of these buyout rumors and potential valuation scenarios, while simultaneously monitoring technical flag patterns and the company's significant debt obligations that complicate a prospective deal.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume following confirmation of production orders and a direct business relationship with Marvell, fueling investor excitement about its role in AI infrastructure. The community is actively debating the stock's transition from speculative R&D to a commercial scaling phase, with bullish sentiment driven by the company's patented optical interposer technology and anticipated hyperscaler partnerships.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending as investors focus on its potential as a critical player in the nuclear and semiconductor supply chain, particularly amid supply chain constraints and geopolitical tensions affecting helium and isotope markets. The community is actively monitoring for milestone updates regarding commercial production and shipments of Si-28 and other isotopes, often expressing frustration over project timelines while remaining bullish on the firm's long-term strategic value.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following the announcement of its acquisition of LivePerson, a move investors are evaluating as a strategic effort to consolidate voice and digital messaging capabilities into a unified omnichannel AI platform. While bullish community members highlight the immediate expansion of the enterprise customer base and cross-selling potential, the stock is seeing heightened volatility as traders weigh the integration risks and the impact of the deal on the company's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.</li><li>Regeneron will lower the Medicaid prices of its products to match those in other developed nations.</li><li>REGN commits $9 billion in domestic R&amp;D and manufacturing capacity.</li></ul>Regeneron Pharmaceuticals (REGN) on Thursday became the 17th and the final biopharma firm to sign Trump’s drug pricing agreement, which is a pledge to lower the cost of current and future life-altering medications.&nbsp;The deal commits Regeneron to lower prices on its current and future medicines for Medicaid patients to match the lowest rates paid in other developed nations. As part of the pact, the company will sell its blockbuster cholesterol drug Praluent for $225 — down from roughly $537 — through the TrumpRx.gov direct-to-consumer platform."For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation — effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.&nbsp;“Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation.”&nbsp;Regeneron is the last of the original 17 pharmaceutical companies that received letters from Trump in July 2025, urging them to lower drug prices in the U.S. to levels paid by other developed nations.&nbsp;Companies that have already signed similar agreements include AbbVie, Amgen, AstraZeneca, Eli Lilly, GSK and Sanofi.<h2 class="st-heading-2">Otarmeni Approval And Sale</h2>REGN on Thursday also announced that its gene therapy for genetic hearing loss, Otarmeni, received accelerated approval from the U.S. Food and Drug Administration (FDA), and the firm will be providing the treatment free of cost to Americans.&nbsp;As part of the MFN agreement, Regeneron will not be subject to future pricing mandates and will receive three years of tariff relief through an agreement with the U.S. Department of Commerce. The company also committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.<h2 class="st-heading-2">What is Trump’s MFN</h2>The&nbsp;Most-Favored-Nation (MFN) policy is a signature healthcare initiative of the Trump administration designed to ensure that Americans do not pay more for prescription drugs than patients in other developed countries.Participating companies agree to offer deeply discounted pricing on drugs supplied to Medicaid and through the TrumpRx.gov platform.<h2 class="st-heading-2">Retail Take</h2>Retail sentiment on Stocktwits&nbsp;around REGN stock was ‘bullish’ with ‘high’ message volumes.&nbsp;One user highlighted he was bullish on REGN and UNH shares.&nbsp;<stembedurl>https://stocktwits.com/DrAzevedo/message/616338118</stembedurl> The stock lost 0.8% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

REGN becomes the final of the 17 drugmakers contacted by President Trump last year to sign his most favored nation (MFN) pricing agreement. 

Equity

European Commission Approves MRNA's COVID-19-Influenza Combo Shot

Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.

GSK (GSK) Earnings Expected to Grow: Should You Buy?

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Expected to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK) will be releasing its Q1 2026 earnings before the market opens on Wednesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-29-glaxosmithkline-plc-stock...

GSK (LON:GSK) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

GSK (LON:GSK) Stock Price Crosses Above 200 Day Moving Average - Time to Sell...

Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk

FDA court freeze leaves COVID, flu, RSV vaccines in limbo as Kennedy's ACIP overhaul faces legal challenge.read more...

Farther Finance Advisors LLC Grows Stock Position in GSK PLC Sponsored ADR $GSK

Farther Finance Advisors LLC increased its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 146.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm...

GSK PLC Sponsored ADR $GSK Shares Sold by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY trimmed its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent 13F...

Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?

MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.

SMMT Stock Up 24% in Three Months: Here's What You Need to Know

Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GSK News

GSKGlaxosmithkline plc - ADR